Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
The chart shows the growth of an initial investment of $10,000 in Exelixis Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Exelixis Inc (EXEL) has returned 0.83% so far this year and 31.53% over the past 12 months. Looking at the last ten years, EXEL has achieved an annualized return of 26.48%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Exelixis Inc (EXEL) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.96% | 4.88% | 2.12% | 1.95% | ||||||||
| 2025 | -1.16% | 17.96% | -4.85% | 6.44% | 10.02% | 1.23% | -17.85% | 3.31% | 10.87% | -6.37% | 17.63% | -0.03% |
| 2024 | -8.92% | 0.69% | 7.81% | -0.47% | 0.23% | 4.08% | 4.59% | 10.72% | 0.31% | 27.79% | 9.03% | -8.59% |
| 2023 | 9.92% | -2.57% | 13.64% | -5.43% | 5.36% | -1.24% | 3.46% | 13.42% | -3.15% | -6.32% | 5.67% | 9.89% |
| 2022 | -0.71% | 12.80% | 11.02% | -2.15% | -17.47% | 14.21% | 0.67% | -15.32% | -11.56% | 4.28% | 0.65% | -6.25% |
| 2021 | 10.06% | -3.73% | 3.34% | 8.17% | -8.63% | -19.38% | -7.77% | 12.63% | 9.82% | 1.85% | -22.20% | 8.42% |
| 2020 | -2.88% | 8.27% | -7.17% | 47.61% | 1.48% | -3.57% | -3.43% | -4.68% | 10.58% | -16.71% | -7.66% | 3.35% |
| 2019 | 22.25% | -4.97% | 4.02% | -18.05% | -0.96% | 9.03% | -2.48% | -8.40% | -10.86% | -12.96% | 6.81% | 5.64% |
| 2018 | -0.13% | -14.94% | -13.95% | -5.02% | -0.34% | 3.26% | -2.54% | -7.98% | -4.99% | -21.73% | 46.22% | -6.24% |
| 2017 | 19.68% | 18.10% | -0.46% | 3.51% | -17.07% | 31.57% | 9.85% | 7.46% | -17.72% | 1.89% | 8.54% | 12.30% |
| 2016 | 16.71% | 40.17% | 21.09% | 16.94% | 21.59% | 14.91% | -18.48% | 60.08% | -12.29% |
The charts below present risk-adjusted performance metrics for Exelixis Inc (EXEL) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of EXEL compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Exelixis Inc volatility is 1.48%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.95B | 2.94B | 3.07B | 2.14B | 1.89B | 1.42B | 655.29M | 597.54M | 327.96M | 503.29M | 721.10M | 393.26M |
| Equity Attributable To Parent (USD) | 2.24B | 2.26B | 2.49B | 1.88B | 1.69B | 1.29B | 284.96M | 89.32M | -114.83M | 66.24M | 296.43M | 90.63M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 2.24B | 2.26B | 2.49B | 1.88B | 1.69B | 1.29B | 284.96M | 89.32M | -114.83M | 66.24M | 296.43M | 90.63M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | 48.51M | - | 1.96M | 7.22M | - |
| Long-term Debt (USD) | - | - | - | - | - | - | - | 189.12M | 361.66M | 347.24M | 335.74M | 214.13M |
| Noncurrent Liabilities (USD) | 299.72M | 284.17M | 258.70M | 53.56M | 56.95M | 29.36M | 255.16M | 237.64M | 270.93M | 349.20M | 342.96M | 210.31M |
| Other Current Liabilities (USD) | 365.58M | 360.51M | 291.69M | 181.03M | 131.17M | 94.57M | 105.60M | 264.02M | 165.45M | 78.51M | 77.31M | 90.37M |
| Accounts Payable (USD) | 38.19M | 33.77M | 32.67M | 23.63M | 11.58M | 10.90M | 9.58M | 6.57M | 6.41M | 9.35M | 4.40M | 1.96M |
| Current Liabilities (USD) | 403.77M | 394.28M | 324.36M | 204.66M | 142.75M | 105.47M | 115.17M | 270.59M | 171.86M | 87.85M | 81.70M | 92.33M |
| Liabilities (USD) | 703.49M | 678.45M | 583.06M | 258.22M | 199.70M | 134.83M | 370.33M | 508.22M | 442.79M | 437.05M | 424.66M | 302.63M |
| Other Non-current Assets (USD) | 1.36B | 1.50B | 1.34B | 624.55M | 825.59M | 474.37M | 144.68M | 124.67M | 158.29M | 231.77M | 282.50M | 155.93M |
| Fixed Assets (USD) | 119.39M | 128.73M | 110.62M | 67.38M | 48.89M | 50.90M | 25.74M | 2.07M | 2.43M | 4.91M | 6.06M | 8.51M |
| Noncurrent Assets (USD) | 1.48B | 1.62B | 1.45B | 691.94M | 874.48M | 525.27M | 170.42M | 126.74M | 160.72M | 236.68M | 288.56M | 164.44M |
| Other Current Assets (USD) | 1.18B | 1.06B | 1.37B | 1.26B | 879.23M | 724.41M | 397.03M | 425.22M | 15.68M | 259.78M | - | - |
| Inventory (USD) | 22.39M | 17.32M | 33.30M | 20.97M | 12.89M | 9.84M | 6.66M | 3.34M | 2.38M | 2.89M | - | - |
| Accounts Receivable (USD) | 265.44M | 237.41M | 214.78M | 160.88M | 119.07M | 162.77M | 81.19M | 42.25M | 4.88M | 3.94M | - | - |
| Cash (USD) | - | - | - | - | - | - | - | - | 144.30M | - | - | - |
| Current Assets (USD) | 1.47B | 1.32B | 1.62B | 1.45B | 1.01B | 897.02M | 484.87M | 470.80M | 167.24M | 266.61M | 432.54M | 228.82M |
| Assets (USD) | 2.95B | 2.94B | 3.07B | 2.14B | 1.89B | 1.42B | 655.29M | 597.54M | 327.96M | 503.29M | 721.10M | 393.26M |
The article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful Cabometyx therapy and promising pipeline candidates like zanzalintinib.
Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.
InSilico Medicine, fresh from Hong Kong's biggest 2025 IPO raising HK$2.28 billion, announced a multi-year drug discovery partnership with French pharmaceutical company Servier worth up to $888 million. The deal leverages InSilico's AI platform for cancer drug development. Despite strong investor backing and rapid pipeline progress, the company faces profitability challenges with volatile revenue heavily dependent on partnership payments.
The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx and an upcoming next-generation cancer medicine Zanzalintinib in phase 3 trials for metastatic colorectal cancer.
The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.
Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.
Merck and Eisai reported positive Phase 3 trial results for their cancer therapy combination Welireg and Lenvima in treating advanced renal cell carcinoma, demonstrating significant improvement in progression-free survival compared to rival treatments.
Exelixis is a biotech company with a strong market position in cancer drugs, particularly kidney cancer treatment Cabometyx. The company is profitable, has promising drug candidates like zanzalintinib, and is well-positioned for future growth in oncology.
The pancreatic endocrine tumor market is expected to grow significantly between 2025-2034, driven by novel therapies like Zanzalintinib, RYZ101, and Nab-sirolimus, which could transform treatment approaches for this rare cancer.
Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.